Feb. 2017 Digital Edition
January 2017 Digital Edition
Nov/Dec 2016 Digital Edition
Oct 2016 Digital Edition
Sept 2016 Digital Edition
Aug 2016 Digital Edition
July 2016 Digital Edition
Implant Sciences’ hot technology brings in two large European explosives detection tenders
Implant Sciences of Wilmington, MA has, in the past week, won significant orders in Europe for the company’s QS-B220 explosives and drug detection system. The company sold 75 detection systems to The Netherlands and 66 systems to Norway, according to Dr. Darryl Jones, Implant’s Vice President of Global Sales and Marketing. The company has not announced the value of the orders, but it is estimated that together they're worth $7 million or more. The systems will be used for screening passengers and baggage in airport environments.
The orders come on the heels of Implant’s QS-B220 passing the rigorous European Civil Aviation Conference’s (ECAC) Common Evaluation Process of Security Equipment for airport checkpoint screening of passengers and baggage, and is the first Explosives Trace Detector (ETD) company to do so. The Common Evaluation Process provides standards for security equipment performance across ECAC’s 44 member nations.
In a recent press release, Dr. Jones noted that "after weeks of testing and thousands of samples, the customer informed (them) that the QS-B220 had the lowest false alarm rate out of all of the tested systems. When screening millions of passengers per year, false alarms carry a tremendous monetary cost and are disruptive to security operations and passenger experience…The selection of Implant Sciences by this customer, reinforced by the recent U.S. aviation procurement, demonstrates that the QS-B220 is well suited to deliver superior results for high-throughput airports, where false alarm rates matter the most."
On a roll
Implant has been on a roll recently. The company won the largest order in its history in December from the Transportation Security Administration (TSA) for 1170 QS-B220s, which will be installed in airports throughout the U.S. to protect the traveling public. That award was protested by Morpho Detection, a unit of the giant conglomerate Safran, headquartered in Paris. The protest was dismissed by the U. S. Government Accountability Office, which reprimanded Morpho for its inability to meet false alarm standards. The company also has announced a number of other recent orders, including a $750,000 order in Asia for military, aviation and critical infrastructure protection that was announced March 23.
Implant Sciences has earned challenging certifications not only from certification bodies in the U. S. and across Europe, but from other authorities across the globe, including China’s Civil Aviation authority and its Ministry of Public Security, as well as agencies in France, Germany and Russia. In fact, the QS-B220 is now the most widely deployed non-radiation desktop ETD in the world.
Having focused all its research and development on its explosives and drug detection capabilities, Implant Sciences indicates that its recent string of important orders confirms that security professionals worldwide are finding the company’s technology to be superior to the old legacy systems which have been in place for the past decade.